These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12708638)

  • 1. Connecting the role of C-reactive protein and statins in cardiovascular disease.
    Ridker PM
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III39-44. PubMed ID: 12708638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Kones R
    Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels.
    Blake GJ; Ridker PM; Kuntz KM
    J Am Coll Cardiol; 2002 Jul; 40(1):49-55. PubMed ID: 12103255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    Albert MA; Danielson E; Rifai N; Ridker PM;
    JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance for lowering C-reactive protein with statins.
    Arévalo-Lorido JC
    Ann Med; 2016 Nov; 48(7):516-524. PubMed ID: 27355392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison of dietary portfolio vs statin on C-reactive protein.
    Jenkins DJ; Kendall CW; Marchie A; Faulkner DA; Josse AR; Wong JM; de Souza R; Emam A; Parker TL; Li TJ; Josse RG; Leiter LA; Singer W; Connelly PW
    Eur J Clin Nutr; 2005 Jul; 59(7):851-60. PubMed ID: 15900306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ; Watson KE; Weiss RE; Fonarow GC
    Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
    Ridker PM; Bhatt DL; Pradhan AD; Glynn RJ; MacFadyen JG; Nissen SE;
    Lancet; 2023 Apr; 401(10384):1293-1301. PubMed ID: 36893777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of C-reactive protein on treatment of patients with cardiovascular disease.
    Gortney JS; Sanders RM
    Am J Health Syst Pharm; 2007 Oct; 64(19):2009-16. PubMed ID: 17893410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
    Shishehbor MH; Patel T; Bhatt DL
    Cleve Clin J Med; 2006 Aug; 73(8):760-6. PubMed ID: 16913201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.